Insights from 2024 EHA Annual Meeting
M

EHA 2024 Insights: Golcadomide, an Oral CELMoD, + R-CHOP in Patients With Untreated Aggressive B-Cell Lymphoma

By Insights from 2024 EHA Annual Meeting FEATURING Marc Hoffmann
By Insights from 2024 EHA Annual Meeting FEATURING Marc Hoffmann
30 views
July 18, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Featured Video

07:44
Incyte

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
22:11
SOHO Brazil 2024

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

Feat. A. Zelenetz
22:09
Scripps Health

New Updates in Frontline DLBCL

Feat. L. Nastoupil
27:47
Indy Hematology Review

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Feat. S. Smith
16:34
Jennifer Amengual

Top 5 Lymphoma Abstracts From ASH

35:27
Louisville Hematology Highlights

Updates on Management of DLBCL

Feat. J. Leonard
04:04
Wojciech Jurczak

Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial

10:04
Tara Graff

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

08:01
Georg Lenz

Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC

30:07
Dipenkumar Modi

Current Management of DLBCL From Frontline to Relapsed Disease

33:48
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: B-Cell Lymphoma

Feat. L. Nastoupil
35:24
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

Feat. G. Nowakowski
34:36
MyCancerHaven

Frontline DLBCL Treatment Approaches

Feat. R. Vij, H. Cherng
29:26
Massachusetts General Hospital Cancer Center

Practice-Changing Updates in DLBCL and HL

Feat. J. Erika Haydu
04:29
Juan Pablo Alderuccio

Polatuzumab Vedotin in 1L DLBCL: Perspectives on the POLARIX Trial

62:02
UChicago Medicine

New Treatment Strategies in DLBCL

Feat. L. Sehn
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

06:09
Insights from 2023 ASH Annual Meeting

CLL/SLL: Outcomes of Pts With Richter's Transformation Without …

Feat. A. Kittai
29:59
Houston Methodist

What's Current in Immunotherapy in DLBCL and FL

Feat. A. Mehta
14:17
SOHO Brazil 2024

DLBCL Pts Ineligible for CAR-T Therapy: Do They Exist and How Do We …

Feat. A. Zelenetz